[{"address1": "200 Granville Street", "address2": "Suite 2820", "city": "Vancouver", "state": "BC", "zip": "V6C 1S4", "country": "Canada", "phone": "604 336 7906", "website": "https://www.aequuspharma.ca", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.", "fullTimeEmployees": 12, "companyOfficers": [{"maxAge": 1, "name": "Mr. Douglas Glen Janzen", "age": 54, "title": "Chairman, CEO & President", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 153289, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ann  Fehr CGA, CPA", "age": 54, "title": "CFO & Corporate Secretary", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 101177, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Grant  Larsen", "title": "Chief Commercial Officer", "fiscalYear": 2022, "totalPay": 181779, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.0116, "open": 0.0079, "dayLow": 0.0079, "dayHigh": 0.014, "regularMarketPreviousClose": 0.0116, "regularMarketOpen": 0.0079, "regularMarketDayLow": 0.0079, "regularMarketDayHigh": 0.014, "beta": 0.373, "volume": 22395, "regularMarketVolume": 22395, "averageVolume": 33604, "averageVolume10days": 3246, "averageDailyVolume10Day": 3246, "marketCap": 1971525, "fiftyTwoWeekLow": 0.0079, "fiftyTwoWeekHigh": 0.04, "priceToSalesTrailing12Months": 3.3581078, "fiftyDayAverage": 0.0161122, "twoHundredDayAverage": 0.02481565, "currency": "USD", "enterpriseValue": 5633398, "floatShares": 112794973, "sharesOutstanding": 132634000, "heldPercentInsiders": 0.1468, "impliedSharesOutstanding": 157722000, "bookValue": -0.027, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -3269430, "trailingEps": -0.01, "enterpriseToRevenue": 9.595, "enterpriseToEbitda": -2.188, "52WeekChange": -0.30939227, "SandP52WeekChange": 0.33757293, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "AQSZF", "underlyingSymbol": "AQSZF", "shortName": "AEQUUS PHARMACEUTICALS INC", "longName": "Aequus Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1434461400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "69ca53f2-e460-3763-b252-eb51c2814c3d", "messageBoardId": "finmb_247433914", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.0125, "recommendationKey": "none", "totalCash": 112022, "totalCashPerShare": 0.001, "ebitda": -2574129, "totalDebt": 4087490, "quickRatio": 0.044, "currentRatio": 0.118, "totalRevenue": 587094, "revenuePerShare": 0.004, "returnOnAssets": -0.83913004, "freeCashflow": -943166, "operatingCashflow": -1838341, "revenueGrowth": -0.962, "grossMargins": 0.74037004, "operatingMargins": -57.78314, "financialCurrency": "CAD", "trailingPegRatio": null}]